Menu Search
Equities

Bavarian Nordic A/S

BAVA:CPH

Bavarian Nordic A/S

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (DKK)198.40
  • Today's Change5.95 / 3.09%
  • Shares traded387.66k
  • 1 Year change+30.27%
  • Beta1.7114
Data delayed at least 15 minutes, as of Nov 22 2024 15:59 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in DKKIncome statement in DKKView more

Year on year Bavarian Nordic A/S grew revenues 124.14% from 3.15bn to 7.06bn while net income improved from a loss of 347.38m to a gain of 1.48bn.
Gross margin52.38%
Net profit margin18.43%
Operating margin18.83%
Return on assets8.18%
Return on equity11.17%
Return on investment10.46%
More ▼

Cash flow in DKKView more

In 2023, Bavarian Nordic A/S increased its cash reserves by 156.73%, or 901.83m. The company earned 1.12bn from its operations for a Cash Flow Margin of 15.85%. In addition the company generated 735.83m cash from financing while 945.56m was spent on investing.
Cash flow per share22.12
Price/Cash flow per share8.82
Book value per share136.86
Tangible book value per share54.65
More ▼

Balance sheet in DKKView more

Bavarian Nordic A/S uses little debt in its capital structure as supported by a debt to capital ratio of 1.06%.
Current ratio1.69
Quick ratio0.976
Total debt/total equity0.0107
Total debt/total capital0.0106
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.